Patient Guide: Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced Ex Vivo with the UNC13D LV Vector Expressing the UNC13D CDNA

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

✓ Get matched to the right study location for you
✓ Connect directly with study coordinators at 1 participating sites
✓ Understand eligibility with our simplified screening tool
✓ Free service - we're here to help you access clinical research

Trial ID: NCTNCT06736080

Status: NOT_YET_RECRUITING

Condition: Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)

Phase: PHASE1, PHASE2

Find a Study Location Near You

This study is available at 1 research site. We'll help you connect with the location that's right for you.

Participating sites include:

• Paris,

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced Ex Vivo with the UNC13D LV Vector Expressing the UNC13D CDNA - Join Clinical Trial NCTNCT06736080

How to Join This Clinical Trial - NCTNCT06736080

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). Current status: NOT_YET_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied: Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)
Treatment Being Tested: Investigational treatment
Study Phase: PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status: NOT_YET_RECRUITING
Study Identifier: NCTNCT06736080 - ClinicalTrials.gov Identifier
Sponsored By: Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

Initial screening to determine eligibility
Regular study visits and health assessments
Receiving the study treatment or placebo
Medical monitoring and follow-up care
Contributing to medical research that may help others
Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

Close medical monitoring by healthcare professionals
Access to potential new treatments
Compensation for time and travel (varies by study)
No-cost study-related medical care
The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 1 locations. Find a study site near you:

Clinical Research Site

Paris, 75015 - France

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3):

Review the eligibility criteria with your healthcare provider
Contact the study team for a pre-screening interview
Schedule an in-person screening visit if eligible
Review and sign the informed consent form
Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

Find clinical trials that match your condition
Get matched to the right study location near you
Connect directly with study coordinators
Understand if you qualify with simplified eligibility screening
Navigate the enrollment process with personalized support
Access new treatments through clinical research participation